Perineural invasion (PNI), the infiltration of nerves by tumor cells, is a hallmark of pancreatic ductal adenocarcinoma (PDAC); however, despite being a clinically relevant phenomenon, the mechanisms underlying PNI remain poorly understood. Most currently available in vitro and ex vivo models rely on murine-sourced n...
Regina A. Casimiro-Núñez, Sydney Willey, Harrison L. Hiraki et al.· Cancer Research· 0 citations
KMT2D, a histone H3K4 methyltransferase and critical epigenetic regulator, is mutated in approximately 11% of pancreatic ductal adenocarcinoma (PDAC) cases. Prior work from our group demonstrated that KMT2D loss drives epithelial-to-mesenchymal plasticity (EMP) and tumor progression in PDAC; however, the downstre...
Raghunath Ranga Sudharshan, H. Kim, Heizel Acosta et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies and is characterized by a profoundly immunosuppressive tumor microenvironment (TME) that limits the efficacy of current therapies. KMT2D (Mll4 in mice) is a histone H3K4 methyltransferase and critical epigenetic regulator that is altere...
Heizel Acosta, R. Sudharshan, Hongsun C. Kim et al.· Cancer Research· 0 citations
KMT2D plays a pivotal role in orchestrating both tumor-intrinsic and microenvironmental processes that drive pancreatic cancer progression, and understanding how KMT2D loss reprograms the immune landscape may uncover novel immunomodulatory therapeutic targets for pancreatic cancer.
H. Acosta-Vilanova, H. Kim, Shungang Zhang et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
